The hospital counter is where a patient sees the medicine bill. It is not necessarily where the entire difference between procurement cost and the printed maximum retail price is earned. Understanding that chain is essential to judging the business consequences of the Supreme Court’s scrutiny of drug markups.
The Economic Times reported on September 30 that the court had asked the government why a uniform limit of 16% above the price to retailer should not apply to medicine MRPs. The report describes judicial questioning and a request for a government response. It does not establish that a universal new cap has already taken effect. Report of the court proceedings
The proposed reference price makes the mechanism different from a simple percentage cut in every patient’s bill. It would link a permitted selling ceiling to a point in the supply chain. The outcome would depend on which transactions, discounts, products and participants the eventual rule includes.
Markup and profit are different measurements
Consider an arithmetic illustration, not an enacted rule or an actual medicine. If the relevant retailer purchase price were ₹100 and an allowed markup were 16%, the implied MRP would be ₹116. The ₹16 difference is 13.8% of the ₹116 selling price, calculated by Kiwaro. A percentage of purchase cost is not the same percentage of sales, and neither automatically equals net profit.
From that difference a retailer may still have to fund staff, premises, handling, inventory, expiry and other costs. Elsewhere in the chain, a manufacturer’s realised price, a distributor’s discount and a pharmacy’s procurement terms can differ from the printed MRP. Exposure therefore has to be located in actual transactions rather than inferred from an unusually large MRP alone.
This opens a wider institutional question. Pharmacy operators, distributors and suppliers with different product and discount mixes may respond differently to a rule framed around retailer purchase prices. A buyer obtaining substantial procurement discounts has different economics from a retailer purchasing close to standard trade terms. A company selling mostly through competitively priced channels may have a different starting point again.
No company-specific margin loss follows from the court report alone. It would require verified revenue from affected products, actual acquisition and sale prices, contractual discounts and the final regulatory scope. Naming every drug maker or pharmacy chain as equally exposed would conceal the variables that determine the outcome.
Inventory and reimbursement could transmit the change further. If selling terms change while stock purchased on older terms remains in the channel, businesses may need to negotiate returns, credits or new terms. If public or private payers change reimbursement practices, the economics could shift even where a supplier’s own invoice price remains unchanged. These are conditional routes to investigate, not observed losses.
The next substantive evidence is the government’s response and any operative pricing instrument. Their treatment of the purchase-price base and the products covered will matter more than a headline percentage detached from those definitions.
The durable reporting opportunity is to follow the money from manufacturer to patient. That would show whose realised margin changes, whose costs remain and how much of any reduction reaches the buyer of the medicine.
